Oral tebipenem pivoxil hydrobromide shows promise for complicated UTI

Oral tebipenem pivoxil hydrobromide is noninferior to IV ertapenem for the treatment of complicated UTI and acute pyelonephritis, according to the results of a phase 3 trial published in The New England Journal of Medicine.
Angela K. Talley, MD, senior vice president of clinical development at Spero Therapeutics and clinical lead for the tebipenem hydrobromide program, said complicated UTI (cUTI) — including acute pyelonephritis (AP) — affects nearly 3 million people each year in the United States and “presents a substantial clinical and economic burden on the health care system”

Oral tebipenem pivoxil hydrobromide is noninferior to IV ertapenem for the treatment of complicated UTI and acute pyelonephritis, according to the results of a phase 3 trial published in The New England Journal of Medicine.
Angela K. Talley, MD, senior vice president of clinical development at Spero Therapeutics and clinical lead for the tebipenem hydrobromide program, said complicated UTI (cUTI) — including acute pyelonephritis (AP) — affects nearly 3 million people each year in the United States and “presents a substantial clinical and economic burden on the health care system”